THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25
Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024
Read more at globenewswire.comThird Harmonic Bio Announces Third Quarter 2024 Financial Results
THIRD HARMONIC BIO INC
NASDAQ:THRD (2/11/2025, 10:57:07 AM)
3.29
-1.36 (-29.25%)
THRD Latest News and Analysis
43 minutes ago - ChartmillTuesday's session: gap up and gap down stocksLet's have a look at the gap up and gap down stocks in today's session.
3 hours ago - ChartmillWhich stocks are moving before the opening bell on Tuesday?As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
